Dr Shilpa Gupta is a hemato-oncologist with 16 years of experience in diagnosing and treating blood cancers and related blood disorders. She is associated with HCG Cancer Hospital, Borivali, in the Department of Hemato-Oncology and Cellular Therapy.
Her work covers conditions such as leukaemia, lymphoma, multiple myeloma and myelodysplastic syndromes. She also manages patients with anaemia, platelet disorders and low blood cell counts. Her treatment experience includes chemotherapy, immunotherapy, bone marrow transplantation and CAR-T cell therapy. She works with adult patients, including those whose blood cancers have returned after treatment.
Diagnosis and treatment of adult leukaemia, lymphoma and multiple myeloma
Management of other blood disorders
Chemotherapy and immunotherapy for blood cancers
Bone marrow transplantation
CAR-T cell therapy
Accepted on 24/03/2026 for publication in Mediterranean Journal of Hematology and Infectious diseases. Gupta et al. Simultaneous presentation of Hemophagocytic Lymphohistiocytosis and Classical Hodgkin's Lymphoma in a patient with underlying germline homozygous STXBP2 Mutation.
Primary extranodal classical Hodgkin lymphoma presenting as a chest wall mass mimicking tuberculosis: A rare case report with long-term follow-up (P. Jujjuvarapu, S. Gupta, & V. . Dalal, Trans.). (2026). Indian Journal of Case Reports, 11(12), 634-637.
Gupta S. Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series. Leukemia & Lymphoma,2012.
Book Chapter: Gastrointestinal Lymphomas in Recent Advances in Surgery - 2012, Jaypee Publications.
Peer-review journal reviewer Principal Investigator / Co-Investigator in multiple trials, including:
2024 | Phase III | Observational study on anticoagulant prescribing patterns - Principal Investigator. 2023 | Phase III | PZN-128 in Chronic ITP - Principal Investigator. Earlier experience: Multiple Phase III trials in colorectal cancer, breast cancer, T-cell lymphoma, ovarian cancer, and pancreatic cancer (2015-2017).
PI: Phase II/III trial of masitinib with dexamethasone and gemcitabine in relapsed/refractory peripheral T-cell lymphoma. (National, Completed 2016)
Co-I: BA-BE study of Mylan's Doxorubicin Hydrochloride Liposome vs. Sun Pharma's reference in ovarian cancer patients after platinum chemotherapy. (National, Completed 2017)
Co-I: Phase III study of Selinexor, Bortezomib, and Dexamethasone (SVd) in relapsed/refractory multiple myeloma. (International, Completed 2018)
Co-I: BA-BE study comparing Zydus Rituximab vs. Roche/Genentech reference in DLBCL. (National, Completed 2018)
Co-I: BA-BE study comparing Cadila Trastuzumab Emtansine vs. Kadcyla (Roche) in HER2-positive metastatic breast cancer. (National, Completed 2018)
PI: Phase III international study of PZN-128 subcutaneous injection vs. comparator in chronic immune thrombocytopenic purpura. (Completed 2023)
PI: Observational study on anticoagulant prescription factors and outcomes. (Investigator-initiated, Completed 2024)
Awarded “Promising Oncologist Award” at Times group at Times Oncology Conclave, 3rd Prize – Poster Presentation, European School of Oncology / ICML, 2012
Awarded JRD Tata Scholarship and Ratan Tata (M.B.B.S.) | Distinction in Microbiology & Biochemistry
Ranked 142nd in PGM-CET 2006; 33rd in MH- CET 2000
Feel free to reach out to us.